Scientific Reports · 2017 · 40 citations · 36 references
PharmacyOncologyPharmacologyCancer PharmacologyImmunotherapyTumor ImmunologyAntibody CharacterizationAntibody FunctionAntibody PharmacokineticsCancer GlycobiologyGlycoengineering Of AntibodiesPharmacokinetics Of Monoclonal AntibodiesAntibodiesAntibody Glycosylation EffectsAntibody-dependent Cellular CytotoxicityGlycoengineering For Cancer ImmunotherapyGlycoengineering Of Monoclonal AntibodiesPertuzumab TherapySialylated AntibodiesTherapeutic Antibody Glycoengineering
Abstract Pertuzumab is an antihuman HER2 antibody developed for HER2 positive breast cancer. Glycosylation profiles are always the important issue for antibody based therapy. Previous findings have suggested the impact of glycosylation profiles on the function of antibodies, like pharmacodynamics, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, the roles of fucose and sialic acid in the function of therapeutic antibodies still need further investigation, especially the role of sialic acid in nonfucosylated antibodies. This study focused on the pharmacokinetic and pharmacodynamic properties of pertuzumab after glycoengineering. Herein, nonfucosylated pertuzumab was produced in CHO FUT8 −/− cells, and desialylated pertuzumab was generated by enzymatic hydrolysis. Present data indicated that fucose was critical for ADCC activity by influencing the interaction between pertuzumab and FcγRIIIa, nevertheless removal of sialic acid increased the ADCC and CDC activity of pertuzumab. Meanwhile, regarding to sialic acid, sialidase hydrolysis directly resulted in asialoglycoprotein receptors (ASGPRs) dependent clearance in hepatic cells in vitro . The pharmacokinetic assay revealed that co-injection of asialofetuin can protect desialylated pertuzumab against ASGPRs-mediated clearance. Taken together, the present study elucidated the importance of fucose and sialic acid for pertuzumab, and also provided further understanding of the relationship of glycosylation/pharmacokinetics/pharmacodynamics of therapeutic antibody.
36
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2015 · 11.9K citations · Full text
Toyohide Shinkawa, Kazuyasu Nakamura, Naoko Yamane et al. · Journal of Biological Chemistry · 2003 · 1.4K citations · Full text
Sandra M. Swain, Sung‐Bae Kim, Javier Cortés et al. · The Lancet Oncology · 2013 · 1K citations · Full text
Medicine, Oncology, Pharmacology +16